FDA 483 OBSERVATION · #3 OF 1,923 MOST-CITED
Lack of or inadequate complaint procedures
FDA cited this observation 1,772 times across 1,592 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.
What this grouping is not
An observation-type page groups FDA’s published citation records. The grouping, the compliance steps and the root causes are SPEQ synthesis, not an FDA classification of any citation, and a count measures what FDA published rather than risk.
What this observation means, and how to comply
SPEQ's practitioner reading of this finding. The regulatory basis is a cited fact; the interpretation, compliance steps, and root causes are SPEQ synthesis — not an FDA classification of the citation.
The firm lacked adequate written procedures for receiving, reviewing, and evaluating complaints, or did not follow them — including failing to decide whether each complaint needed investigation and, for devices, whether it was reportable to FDA as an MDR.
Why FDA writes it — Complaints are the firm’s early-warning system for field failures. A weak complaint-handling process means real product problems go uninvestigated, trends go unseen, and reportable events are never reported — which is why FDA treats it as a high-signal finding.
- Establish a formally designated unit and a written procedure that ensures all complaints are processed uniformly and in a timely manner, and that oral complaints are documented.
- Require a documented decision on whether each complaint warrants investigation — and if not, record the reason and who made the call.
- For devices, build the MDR reportability decision into the complaint workflow so events meeting 21 CFR 803 criteria are captured and reported on time.
- Trend complaints to detect signals a single record would miss, and feed confirmed problems into CAPA.
- Complaints handled ad hoc by whoever answers the phone, with no consistent intake, evaluation, or reportability screen.
- No linkage between complaint handling and CAPA/MDR, so individually “minor” complaints never aggregate into an investigated trend.
How to close this finding — and stop it recurring
What this observation is associated with
Firms cited for this observation also appear in FDA compliance actions — warning letters, injunctions, or seizures — at 1.1× the rate of the average FDA-cited firm (8.7% vs 7.8%), across 1,592 FEI-matched firms.
This is an association, not causation, and reflects co-occurrence in FDA's records — not a claim that the observation caused or preceded the action.
How FDA worded it — real examples
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Procedures for receiving, reviewing, and evaluating complaints by a formally designated unit have not been adequately established.
Related SPEQ references
Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.
Examples are a representative sample of FDA's published inspection observations. Open the 483 observation explorer →